These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18480653)

  • 1. Can we cause regression of coronary atherosclerosis?
    Alsafwah S; Ramanathan KB
    Am J Med Sci; 2008 May; 335(5):368-74. PubMed ID: 18480653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of ACAT inhibition to retard atherosclerosis.
    Fazio S; Linton M
    N Engl J Med; 2006 Mar; 354(12):1307-9. PubMed ID: 16554534
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.
    Nicholls SJ; Sipahi I; Schoenhagen P; Wisniewski L; Churchill T; Crowe T; Goormastic M; Wolski K; Tuzcu EM; Nissen SE;
    Am Heart J; 2006 Jul; 152(1):67-74. PubMed ID: 16824833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
    Tardif JC; Grégoire J; L'Allier PL; Anderson TJ; Bertrand O; Reeves F; Title LM; Alfonso F; Schampaert E; Hassan A; McLain R; Pressler ML; Ibrahim R; Lespérance J; Blue J; Heinonen T; Rodés-Cabau J;
    Circulation; 2004 Nov; 110(21):3372-7. PubMed ID: 15533865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ACAT inhibition on the progression of coronary atherosclerosis.
    Nissen SE; Tuzcu EM; Brewer HB; Sipahi I; Nicholls SJ; Ganz P; Schoenhagen P; Waters DD; Pepine CJ; Crowe TD; Davidson MH; Deanfield JE; Wisniewski LM; Hanyok JJ; Kassalow LM;
    N Engl J Med; 2006 Mar; 354(12):1253-63. PubMed ID: 16554527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries.
    Nicholls SJ
    Curr Opin Lipidol; 2009 Dec; 20(6):491-6. PubMed ID: 19593124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization.
    Bates ER
    Am J Cardiol; 2000 Dec; 86(12A):28L-34L. PubMed ID: 11374853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
    Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
    Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regression of coronary atherosclerosis evaluated by angiography. A review of principal trials and critical study].
    Castaigne A; Albo C; Pham I; Saal JP; Verschuren P
    Arch Mal Coeur Vaiss; 1993 Jan; 86 Spec No 1():31-7. PubMed ID: 8215778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular pharmacology (XII). Pharmacologic interventions in the progression of coronary atherosclerosis].
    Rayo Llerena I; Marín Huerta E
    Rev Esp Cardiol; 1995 May; 48(5):341-58. PubMed ID: 7792429
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lipid lowering after percutaneous coronary intervention. Intended and achieved treatment goals in real life].
    Germing A; Lindstaedt M; Mügge A
    Med Klin (Munich); 2005 Dec; 100(12):781-4. PubMed ID: 16453092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do the extent and direction of arterial remodelling predict subsequent progression of coronary atherosclerosis? A serial intravascular ultrasound study.
    Sipahi I; Tuzcu EM; Moon KW; Nicholls SJ; Schoenhagen P; Zhitnik J; Crowe TD; Kapadia S; Nissen SE
    Heart; 2008 May; 94(5):623-7. PubMed ID: 18070944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound.
    von Birgelen C; Hartmann M; Mintz GS; Baumgart D; Schmermund A; Erbel R
    Circulation; 2003 Dec; 108(22):2757-62. PubMed ID: 14623804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent.
    Kramsch DM
    Int J Cardiol; 1997 Dec; 62 Suppl 2():S119-24. PubMed ID: 9488203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pixel or death: experience from clinical trials assessing lipid lowering therapy.
    Barth JD
    Can J Cardiol; 1995 May; 11 Suppl C():9C-14C. PubMed ID: 7750051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
    Burton JR; Teo KK; Buller CE; Plante S; Catellier D; Tymchak W; Taylor D; Dzavik V; Montague TJ;
    Can J Cardiol; 2003 Apr; 19(5):487-91. PubMed ID: 12717482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis.
    Brown BG
    Eur Heart J; 1992 Jul; 13 Suppl B():17-20. PubMed ID: 1644095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.